Why AV Integrators Don’t Want Electrician’s Licenses: Ratified

 

This episode of Ratified is trying something new; a considerably more niche topic. Whereas the last two went a little larger in scale, hitting on gig economy legislation in California and the state of net neutrality, this episode of Ratified is a look at the nitty gritty legislative back and forth of lobbying in the telecom and AV industry.

Joining Daniel to provide context and perspective is Chuck Wilson, Executive Director of the National Systems Contractors Association, and Keith Kempenich of the North Dakota House of Representatives, representing District 39.

In 2019, legislative sessions introduced new language that would’ve either subtly or drastically changed the dynamics of licensing requirements for electricians and tangential industries, like AV and telecom. Lawmakers looked around at technology they thought was new, or at least now more relevant in these industries, and decided it was time to rework licensing around low-voltage lighting, IoT devices, and power over ethernet. This language was meant to keep everyone safe and adjust legal language for the times.

If only it were that simple. The different state bills immediately turned the heads of AV industry professionals, and not out of excitement. Listen to the full episode to hear how this battle turned out and get the different perspectives from individuals on both sides of the issue.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More